ES2969253T3 - Las opciones sintéticas novedosas hacia la fabricación de (6R,10S)-10-{4-[5-cloro-2-(4-cloro-1H-1,2,3-triazol-1-il)fenil]-6-oxo-1(6H)-pirimidinil}-1-(difluorometil)-6-metil-1,4,7,8,9,10-hexahidro-11,15-(meteno)pirazolo[4,3-b][1,7]diazaciclotetradecin-5(6H)-ona - Google Patents

Las opciones sintéticas novedosas hacia la fabricación de (6R,10S)-10-{4-[5-cloro-2-(4-cloro-1H-1,2,3-triazol-1-il)fenil]-6-oxo-1(6H)-pirimidinil}-1-(difluorometil)-6-metil-1,4,7,8,9,10-hexahidro-11,15-(meteno)pirazolo[4,3-b][1,7]diazaciclotetradecin-5(6H)-ona Download PDF

Info

Publication number
ES2969253T3
ES2969253T3 ES20721374T ES20721374T ES2969253T3 ES 2969253 T3 ES2969253 T3 ES 2969253T3 ES 20721374 T ES20721374 T ES 20721374T ES 20721374 T ES20721374 T ES 20721374T ES 2969253 T3 ES2969253 T3 ES 2969253T3
Authority
ES
Spain
Prior art keywords
compound
acid
formula
alkyl
produce
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES20721374T
Other languages
English (en)
Spanish (es)
Inventor
Nicolas Cuniere
Yu Fan
Sergei Kolotuchin
Subha Mukherjee
Eric M Simmons
Amarjit Singh
Carolyn S Wei
Yi Xiao
Changxia Yuan
Bin Zheng
Simon Albert Wagschal
Diego Fernando Domenico Broggini
Duy Chi Trung Cao
Kostiantyn Chernichenko
Sébastien François Emmanuel LEMAIRE
Haim Cyril Ben
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Bristol Myers Squibb Co
Original Assignee
Janssen Pharmaceutica NV
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV, Bristol Myers Squibb Co filed Critical Janssen Pharmaceutica NV
Application granted granted Critical
Publication of ES2969253T3 publication Critical patent/ES2969253T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES20721374T 2019-04-11 2020-04-10 Las opciones sintéticas novedosas hacia la fabricación de (6R,10S)-10-{4-[5-cloro-2-(4-cloro-1H-1,2,3-triazol-1-il)fenil]-6-oxo-1(6H)-pirimidinil}-1-(difluorometil)-6-metil-1,4,7,8,9,10-hexahidro-11,15-(meteno)pirazolo[4,3-b][1,7]diazaciclotetradecin-5(6H)-ona Active ES2969253T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962832614P 2019-04-11 2019-04-11
PCT/US2020/027655 WO2020210613A1 (en) 2019-04-11 2020-04-10 Novel synthetic options towards the manufacture of (6r,10s)-10- {4-[5-chloro-2-(4-chloro-1h-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6h)- pyrimidinyl}- 1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15 -(metheno)pyrazolo [4,3-b] [1,7] diazacyclotetradecin-5(6h)-one

Publications (1)

Publication Number Publication Date
ES2969253T3 true ES2969253T3 (es) 2024-05-17

Family

ID=70457148

Family Applications (1)

Application Number Title Priority Date Filing Date
ES20721374T Active ES2969253T3 (es) 2019-04-11 2020-04-10 Las opciones sintéticas novedosas hacia la fabricación de (6R,10S)-10-{4-[5-cloro-2-(4-cloro-1H-1,2,3-triazol-1-il)fenil]-6-oxo-1(6H)-pirimidinil}-1-(difluorometil)-6-metil-1,4,7,8,9,10-hexahidro-11,15-(meteno)pirazolo[4,3-b][1,7]diazaciclotetradecin-5(6H)-ona

Country Status (16)

Country Link
US (2) US12378246B2 (cg-RX-API-DMAC7.html)
EP (2) EP4234555A3 (cg-RX-API-DMAC7.html)
JP (2) JP7631218B2 (cg-RX-API-DMAC7.html)
KR (2) KR20260047658A (cg-RX-API-DMAC7.html)
CN (2) CN114375290B (cg-RX-API-DMAC7.html)
AR (1) AR118649A1 (cg-RX-API-DMAC7.html)
AU (2) AU2020272973B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021020368A2 (cg-RX-API-DMAC7.html)
CA (1) CA3132365A1 (cg-RX-API-DMAC7.html)
EA (1) EA202192807A1 (cg-RX-API-DMAC7.html)
ES (1) ES2969253T3 (cg-RX-API-DMAC7.html)
IL (1) IL287102B2 (cg-RX-API-DMAC7.html)
MX (2) MX2025014306A (cg-RX-API-DMAC7.html)
SG (1) SG11202111132WA (cg-RX-API-DMAC7.html)
TW (1) TWI880924B (cg-RX-API-DMAC7.html)
WO (1) WO2020210613A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11788071B2 (en) 2020-04-10 2023-10-17 Codexis, Inc. Engineered transaminase polypeptides
EP4225757A1 (en) * 2020-10-12 2023-08-16 Bristol-Myers Squibb Company A process toward the manufacture of (6r,10s)-10-{4-[5-chloro-2-(4-chloro-1h-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6h)-pyrimidinyl}-1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15-(metheno)pyrazolo[4,3-b] [1,7]diazacyclotetradecin-5(6h)-one

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013033777A2 (pt) * 2011-03-15 2016-09-13 Abbvie Inc moduladores de receptor de hormônio nuclear
JP6505727B2 (ja) 2014-01-31 2019-04-24 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company ヘテロ環式p2’基を有する第xia因子阻害剤としてのマクロ環
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
NO2721243T3 (cg-RX-API-DMAC7.html) * 2014-10-01 2018-10-20
CN105294496A (zh) 2015-09-28 2016-02-03 中山大学 一种西酞普兰中间体的制备方法
CN110062757B (zh) 2017-01-18 2022-03-04 广东东阳光药业有限公司 凝血因子XIa抑制剂及其用途
CN113677682B (zh) 2019-04-16 2023-05-30 华润生物医药有限公司 作为XIa因子抑制剂的大环衍生物
WO2021013209A1 (zh) 2019-07-23 2021-01-28 南京明德新药研发有限公司 作为XIa因子抑制剂的大环衍生物
CA3179679A1 (en) 2020-04-10 2021-10-14 Codexis, Inc. Carboxyesterase polypeptides for kinetic resolution

Also Published As

Publication number Publication date
MX2021012286A (es) 2022-04-06
BR112021020368A2 (pt) 2021-12-07
JP2025084766A (ja) 2025-06-03
US20260092066A1 (en) 2026-04-02
KR20220045105A (ko) 2022-04-12
TW202104188A (zh) 2021-02-01
CA3132365A1 (en) 2020-10-15
JP2022526659A (ja) 2022-05-25
US12378246B2 (en) 2025-08-05
EP3953334A1 (en) 2022-02-16
MX2025014306A (es) 2026-01-07
IL287102B2 (en) 2025-12-01
AR118649A1 (es) 2021-10-20
WO2020210613A1 (en) 2020-10-15
EP4234555A2 (en) 2023-08-30
AU2026201396A1 (en) 2026-03-19
TWI880924B (zh) 2025-04-21
IL287102B1 (en) 2025-08-01
EA202192807A1 (ru) 2022-02-24
CN119775276A (zh) 2025-04-08
US20220144836A1 (en) 2022-05-12
IL287102A (en) 2021-12-01
SG11202111132WA (en) 2021-11-29
CN114375290A (zh) 2022-04-19
AU2020272973A1 (en) 2021-12-02
KR20260047658A (ko) 2026-04-08
KR102929951B1 (ko) 2026-02-24
EP3953334B1 (en) 2023-11-22
CN114375290B (zh) 2024-11-29
EP4234555A3 (en) 2024-01-03
JP7885383B2 (ja) 2026-07-06
JP7631218B2 (ja) 2025-02-18
AU2020272973B2 (en) 2025-11-27

Similar Documents

Publication Publication Date Title
KR102473601B1 (ko) Ep4 길항약과 면역 체크 포인트 저해약을 포함하여 이루어진 조합
EP2855452B1 (en) Substituted pyrrolidines as factor xia inhibitors for the treatment of thromboembolic diseases
ES2733096T3 (es) Intermediarios para la síntesis de ligadores P1 cíclicos como inhibidores del factor XIA
KR100652535B1 (ko) Impdh 효소의 억제제
AU2026201396A1 (en) Novel synthetic options towards the manufacture of (6r,10s)-10-{4-[5-chloro-2-(4-chloro-1h-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6h)-pyrimidinyl}- 1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15-(metheno)pyrazolo[4,3-b][1,7]diazacyclotetradecin-5(6h)-one
ZA200601055B (en) Regioselective synthesis of CCI-779
WO1996040686A1 (en) Heterocyclic substituted cyclopentane compounds
EP3676270A1 (en) Macrocyclic compounds that inhibit mcl-1 protein
JP2022539570A (ja) ニューロキニン-1アンタゴニスト
JP2025156455A (ja) チアゾロ[5,4-b]ピリジンMALT-1阻害剤
CA3195024A1 (en) A process toward the manufacture of (6r,10s)-10-{4-[5-chloro-2-(4-chloro-1h-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6h)-pyrimidinyl}-1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15-(metheno)pyrazolo[4,3-b] [1,7]diazacyclotetradecin-5(6h)-one
EA050867B1 (ru) СПОСОБ ПОЛУЧЕНИЯ (6R,10S)-10-{4-[5-ХЛОРО-2-(4-ХЛОРО-1Н-1,2,3-ТРИАЗОЛ-1-ИЛ)ФЕНИЛ]-6-ОКСО-1(6Н)-ПИРИМИДИНИЛ}-1-(ДИФТОРОМЕТИЛ)-6-МЕТИЛ-1,4,7,8,9,10-ГЕКСАГИДРО-11,15-(МЕТЕНО)ПИРАЗОЛО[4,3-b][1,7]ДИАЗАЦИКЛОТЕТРАДЕЦИН-5(6Н)-ОНА
EP2163553B1 (en) Arene connected polyamine macroring derivatives, preparation methods and pharmaceutical uses thereof
CS354591A3 (en) Aminodiole derivatives, process of their preparation and their use
EP3957638A1 (en) Macrocyclic derivatives acting as xia factor inhibitor
CN104530029A (zh) 作为Xa因子抑制剂的杂环化合物及其使用方法和用途
HK40124045A (en) Novel synthetic options towards the manufacture of a compound
HK1138580B (en) Arene connected polyamine macroring derivatives, preparation methods and pharmaceutical uses thereof